Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxenda in Hypothalamic Obesity
NCT06217848Phase 1Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2022
- Primary completion
- Feb 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liraglutide in hypothalamic obesity (HO), sponsored by Seoul National University Hospital. Primary endpoint: Change in weight at 3 months. Started Nov 2022; status: recruiting.
02
Drugs
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT06217848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217848.